Skip to Content
Long at the forefront of gene-sequencing and -therapy technology, Illumina is picking up steam thanks to the proliferation of DNA sequencing across a variety of medical applications—including tracking infectious diseases like COVID-19. Illumina says there are now some 70 countries using its tech to monitor and analyze samples of the coronavirus, hoping to track how it could mutate into variants. Just as Illumina has helped sharply reduce the cost of genetic sequencing, it aims to do the same for cancer diagnostics via its acquisition of biotech Grail (though the deal faces scrutiny from antitrust regulators).
Courtesy of Illumina
Lists ranking Illumina
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MOREview in list
Change the World - 2021These companies use the creative tools of capitali...READ MOREview in list
Future 50 - 2020Explore this year's ranking of the 50 companies wi...READ MOREview in list